October 19, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today...

recent articles

In response to COVID-19, we are offering the OncoLens Virtual Tumor Board module at no cost, through the end of May, 2020. The module enables cancer care teams to meet completely virtually, in real time, to discuss treatment options for their...

Albuquerque, NM –  April 3, 2020 – Indica Labs, the leading provider of computational pathology software, is pleased to announce the formal release of its HALO AP™ Anatomic Pathology platform at NeoGenomics Laboratories, Inc. HALO...

When you just can’t be in more locations at once and you can’t increase the hours in a day, what do you do? Pathologists need to be able to focus their time on their core expertise, on examining and diagnosing, not on traveling or...

>Interview with pathologists Helen Remotti MD and Ladan Fazlollahi M What do you do and what is your research focus? We are academic pathologists with broad research interests involving liver/gastrointestinal/pancreatic benign and...

OR

platinum partners

gold partners

Silver Partners

Media Partners